Degradation of cartilage proteoglycan by human leukocyte granule neutral proteases--a model of joint injury. I. Penetration of enzyme into rabbit articular cartilage and release of 35SO4-labeled material from the tissue.
The present work was undertaken to explore the effect of two purified neutral proteases derived from human peripheral blood polymorphonuclear leukocytes (PMN) on articular cartilage as a model of joint injury. Human leukocyte elastase and chymotrypsin-like enzyme, purified by affinity chromatography, released 32SO4 from labeled rabbit articular cartilage slices in vitro. Release of isotope was initially delayed, suggesting that either a lag in enzyme penetration occurs or that size of degradation fragments is a limiting factor in diffusion of label out of the tissue. The release of 35SO4 was inhibited by preincubation of elastase and chymotrypsin-like enzyme with human alpha 1-anti-trypsin, or with their specific chloromethyl ketone inactivators, and the action of elastase was also inhibited by a monospecific antiserum to PMN elastase, freed of major serum proteinase inhibitors. Immunohistochemical staining procedures revealed the presence of PMN elastase inside the matrix of cartilage slices after a 20-min exposure of tissue to either the pure enzyme or crude PMN granule extract. Serum alpha 1-antitrypsin failed to penetrate into the cartilage slices under identical in vitro conditions. In association with the results reported in the accompanying paper, these findings suggest a model of cartilage matrix degradation by PMN neutral proteases in which local protease-antiprotease imbalance, coupled with different rates of penetration of protease and antiprotease into target tissue, plays a key role in accounting for matrix damage.
D000818:Animals; D002358:Cartilage, Articular / Q000187:drug effects / Q000378:metabolism*; D002918:Chymotrypsin / Q000302:isolation & purification / Q000494:pharmacology; D003594:Cytoplasmic Granules / Q000378:metabolism*; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006025:Glycosaminoglycans / Q000378:metabolism*; D006801:Humans; D007106:Immune Sera; D007592:Joint Diseases / Q000378:metabolism*; D007700:Kinetics; D007962:Leukocytes / Q000201:enzymology / Q000648:ultrastructure*; D009842:Oligopeptides / Q000494:pharmacology; D010196:Pancreatic Elastase / Q000302:isolation & purification / Q000494:pharmacology; D010447:Peptide Hydrolases / Q000378:metabolism*; D010649:Phenylalanine / Q000031:analogs & derivatives; D011509:Proteoglycans / Q000378:metabolism*; D011817:Rabbits; D013462:Sulfur Radioisotopes; D000515:alpha 1-Antitrypsin / Q000378:metabolism / Q000494:pharmacology
D004791:Enzyme Inhibitors; D006025:Glycosaminoglycans; D007106:Immune Sera; D009842:Oligopeptides; D011509:Proteoglycans; D013462:Sulfur Radioisotopes; D000515:alpha 1-Antitrypsin; D010649:Phenylalanine; D010447:Peptide Hydrolases; D002918:Chymotrypsin; D010196:Pancreatic Elastase